SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (27963)2/7/1999 12:22:00 PM
From: tonyt  Read Replies (1) | Respond to of 32384
 
>I didn't feel like searching through SI to find the major shakeout prediction.

You have never before had problems finding links to you own posts, therefore it is my speculation that you (for reasons only you know) chose to keep this information from the rest of us on SI. I have no problem with this as you were under no obligation to share with us that you knew a MAJOR shakeout was coming at $16



To: Henry Niman who wrote (27963)2/7/1999 12:28:00 PM
From: Machaon  Read Replies (1) | Respond to of 32384
 
<< Other post-approval commitments include a trial to determine the objective response rate in patients whose malignant cells do not express the CD25 component of the IL-2 receptor. >>

Henry, ONTAK is manufactured to search and destroy based on the CD25 component. Would you have any idea why the FDA would want this additional trial based on "not expressing CD25"?

TIA, Bob


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News